Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074967 · ClinicalTrials.gov registry record · Phase 1
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Dan Zandberg.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT04074967 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Dan Zandberg. The registered enrollment target is 70 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04074967, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Dan Zandberg.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selected advanced solid tumors. The Phase II portion will estimate the efficacy of ARRY-614 in combination with either nivolumab or ARRY-614 + nivolumab+ipilimumab immunotherapy in patients with with NSCLC, HNSCC, melanoma and RCC and melanoma.
Conditions Studied
Interventions
- DRUG Phase Ib ARRY-614 + nivolumab
- DRUG Phase Ib ARRY-614 + nivolumab+ipilimumab
- DRUG Phase II ARRY-614 + nivolumab
- DRUG Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
- DRUG Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074967
The ClinicalTrials.gov registry entry for NCT04074967 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Phase Ib ARRY-614 + nivolumab is the first listed.
NCT04074967 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04074967 about?
NCT04074967 is a clinical study titled "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab". In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selected advanced solid t...
What is the current status of trial NCT04074967?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-06-11. Estimated completion is 2025-12-31.
What conditions does trial NCT04074967 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma.
What interventions are being tested in trial NCT04074967?
The interventions under investigation include: Phase Ib ARRY-614 + nivolumab (DRUG), Phase Ib ARRY-614 + nivolumab+ipilimumab (DRUG), Phase II ARRY-614 + nivolumab (DRUG), Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) (DRUG), Phase II ARRY-614 + nivolumab+ipilimumab (RCC) (DRUG).
Who is sponsoring clinical trial NCT04074967?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074967 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.